Extramedullary disease in multiple myeloma: a systematic literature review
- PMID: 35314675
- PMCID: PMC8938478
- DOI: 10.1038/s41408-022-00643-3
Extramedullary disease in multiple myeloma: a systematic literature review
Abstract
Extramedullary involvement (or extramedullary disease, EMD) represents an aggressive form of multiple myeloma (MM), characterized by the ability of a clone and/or subclone to thrive and grow independent of the bone marrow microenvironment. Several different definitions of EMD have been used in the published literature. We advocate that true EMD is restricted to soft-tissue plasmacytomas that arise due to hematogenous spread and have no contact with bony structures. Typical sites of EMD vary according to the phase of MM. At diagnosis, EMD is typically found in skin and soft tissues; at relapse, typical sites involved include liver, kidneys, lymph nodes, central nervous system (CNS), breast, pleura, and pericardium. The reported incidence of EMD varies considerably, and differences in diagnostic approach between studies are likely to contribute to this variability. In patients with newly diagnosed MM, the reported incidence ranges from 0.5% to 4.8%, while in relapsed/refractory MM the reported incidence is 3.4 to 14%. Available data demonstrate that the prognosis is poor, and considerably worse than for MM without soft-tissue plasmacytomas. Among patients with plasmacytomas, those with EMD have poorer outcomes than those with paraskeletal involvement. CNS involvement is rare, but prognosis is even more dismal than for EMD in other locations, particularly if there is leptomeningeal involvement. Available data on treatment outcomes for EMD are derived almost entirely from retrospective studies. Some agents and combinations have shown a degree of efficacy but, as would be expected, this is less than in MM patients with no extramedullary involvement. The paucity of prospective studies makes it difficult to justify strong recommendations for any treatment approach. Prospective data from patients with clearly defined EMD are important for the optimal evaluation of treatment outcomes.
© 2022. The Author(s).
Conflict of interest statement
J.B. has received speaker/lecture honoraria from Janssen, Celgene/BMS, Amgen, Takeda, and Oncopeptides. M.B. has received speaker honoraria from Amgen, Oncopeptides, Janssen, Sanofi, and Takeda. Jo Caers has received research funding from Takeda and Janssen; and honoraria from Janssen, Amgen, BMS-Celgene, and Sanofi. A.J. has received honoraria from Janssen, BMS, Takeda, Sanofi, GSK, Karyopharm, Oncopeptides, and Amgen. M.v.L.-T. has received research funding from Celgene and Oncopeptides; and honoraria from BMS/Celgene, Oncopeptides, Janssen, GSK, and Takeda. Philippe Moreau has received honoraria from Janssen, Celgene, Amgen, AbbVie, Oncopeptides, and Sanofi. Leo Rasche has received honoraria from BMS/Celgene, Sanofi, GSK, Oncopeptides, and Janssen. Laura Rosiñol has received speaker honoraria from Janssen, Celgene, Amgen, Takeda, GSK, and Sanofi. S.Z.U. has received research funding and/or honoraria from Amgen, Celgene, Janssen, Takeda, BMS, Oncopeptides, and Sanofi. E.Z. has received honoraria from, and been an advisory board member for, Janssen, BMS, Takeda, Sanofi, GSK, Karyopharm, Oncopeptides, and Amgen. P.R. has received institutional research support from Oncopeptides, Celgene/BMS, Takeda, and Karyopharm. He has received honoraria for his role as an Advisory Committee member from Karyopharm, Oncopeptides, Celgene/BMS, Takeda, Janssen, Sanofi, Secura Bio, GSK, Regeneron, AstraZeneca, and Protocol Intelligence.
Figures
Similar articles
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Sertindole for schizophrenia.Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
Enamel matrix derivative (Emdogain) for periodontal tissue regeneration in intrabony defects.Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003875. doi: 10.1002/14651858.CD003875.pub2. Cochrane Database Syst Rev. 2005. Update in: Cochrane Database Syst Rev. 2009 Oct 07;(4):CD003875. doi: 10.1002/14651858.CD003875.pub3. PMID: 16235343 Updated.
Cited by
-
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.J Hematol Oncol. 2024 Jun 6;17(1):42. doi: 10.1186/s13045-024-01555-4. J Hematol Oncol. 2024. PMID: 38845015 Free PMC article.
-
Network analysis of master regulators associated with invasive phenotypes in multiple myeloma.Front Cell Dev Biol. 2025 Jul 16;13:1586870. doi: 10.3389/fcell.2025.1586870. eCollection 2025. Front Cell Dev Biol. 2025. PMID: 40741330 Free PMC article.
-
CD38 expression by plasma cells in extramedullary multiple myeloma.Haematologica. 2024 Apr 1;109(4):1297-1300. doi: 10.3324/haematol.2023.284169. Haematologica. 2024. PMID: 37941401 Free PMC article. No abstract available.
-
Circumferential gastric wall thickening as initial presentation of relapsed plasma cell leukemia.Clin Endosc. 2024 Jan;57(1):131-133. doi: 10.5946/ce.2022.291. Epub 2023 Aug 3. Clin Endosc. 2024. PMID: 37536748 Free PMC article. No abstract available.
-
Adoptive Immunotherapy and High-Risk Myeloma.Cancers (Basel). 2023 May 6;15(9):2633. doi: 10.3390/cancers15092633. Cancers (Basel). 2023. PMID: 37174099 Free PMC article. Review.
References
-
- Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548. - PubMed
-
- Bladé J, Fernández de Larrea C, Rosiñol L, Cibeira MT, Jiménez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29:3805–12. - PubMed
-
- Rosiñol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A, et al. Expert review of soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br. J. Haematol. 2021; 10.1111/bjh.17338. - PubMed
-
- Rosiñol L, Fernández de Larrea C, Bladé J. Extramedullary myeloma spread triggered by surgical procedures: an emerging entity? Acta Haematol. 2014;132:36–8. - PubMed